Literature DB >> 14501818

Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.

Zhe Jin1, Shinya Ogata, Gen Tamura, Yousei Katayama, Masayuki Fukase, Mihoko Yajima, Teiichi Motoyama.   

Abstract

The histogenesis of carcinosarcomas (malignant mullerian mixed tumors) of the female genital tract is still not completely understood. In the present study, several different molecular pathologic techniques were applied to determine the histogenesis of 15 uterine and ovarian carcinosarcomas. The patterns of X-chromosome inactivation and the presence of p53 and K-ras mutations were analyzed in the carcinomatous and sarcomatous components. Microsatellite analysis was also performed. Ten tumors were monoclonal, one was biclonal (collision tumor), and another was probably biclonal; the other three were of indeterminate histogenesis. These data indicate that most uterine and ovarian carcinosarcomas are monoclonal.

Entities:  

Mesh:

Year:  2003        PMID: 14501818     DOI: 10.1097/01.pgp.0000092134.88121.56

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  22 in total

1.  Bulky peritoneal carcinosarcoma with tiny high-grade serous carcinoma of the fallopian tube: a case report.

Authors:  Ayaka Nakashima; Yasuyo Maruyama; Haruya Saji; Tomoo Hirabuki; Hiroyuki Mitomi
Journal:  Int Cancer Conf J       Date:  2020-10-19

2.  Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

Authors:  Yihua Liu; Zachary Weber; F Anthony San Lucas; Aditya Deshpande; Yasminka A Jakubek; Raed Sulaiman; Mary Fagerness; Natasha Flier; Joseph Sulaiman; Christel M Davis; Jerry Fowler; David Starks; Luis Rojas-Espaillat; Alexander J Lazar; Gareth E Davies; Erik A Ehli; Paul Scheet
Journal:  Gynecol Oncol       Date:  2018-09-05       Impact factor: 5.482

3.  The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Authors:  Matthieu Le Gallo; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Maria J Merino; David G Mutch; Paul J Goodfellow; James C Mullikin; Daphne W Bell
Journal:  Cancer       Date:  2017-09-21       Impact factor: 6.860

Review 4.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

5.  Carcinosarcoma of female urethra with melanocytic differentiation.

Authors:  Jun Liu; Hong Wu
Journal:  Int J Clin Exp Pathol       Date:  2011-01-30

Review 6.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

8.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Authors:  Eric J Devor; Jillian N DE Mik; Shyam Ramachandran; Michael J Goodheart; Kimberly K Leslie
Journal:  Exp Ther Med       Date:  2012-01-25       Impact factor: 2.447

9.  Primary adrenal sarcomatoid carcinoma metastatic to the lung: Case report and review of the literature.

Authors:  Chuangzhi Zhu; Aiping Zheng; Xiangming Mao; Bentao Shi; Xianxin Li
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

10.  Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.

Authors:  Munveer S Bhangoo; Peter Boasberg; Pareen Mehta; Julia A Elvin; Siraj M Ali; Winnie Wu; Samuel J Klempner
Journal:  Oncologist       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.